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BY-NC-ND license (http://creativecomBackground/purpose: We previously showed that subsequent intrathecal (i.t.) injection of re-
sveratrol (30 mg) significantly reverses morphine-evoked neuroinflammation in morphine-
tolerant rats. The present study examined the underlying mechanism.
Methods: Male Wistar rats were implanted with two i.t. catheters, one of which was connected
to a miniosmotic pump and used for morphine (15 mg/h) or saline infusion for 120 hours. To
examine the effects on spinal cord expression of histone deacetylase 1 (HDAC1), the inflamma-
tory cytokine tumor necrosis factor-a (TNF-a), and TNF receptor (TNFR) 1 and TNFR2 during
tolerance induction, a tail-flick test was performed prior to infusion and after 24 hours, 48
hours, 72 hours, 96 hours, and 120 hours of infusion.
Results: Resveratrol treatment prior to morphine challenge restored the antinociceptive ef-
fect of morphine in morphine-tolerant rats and reversed the morphine infusion-induced in-
crease in HDAC1, TNF-a, and TNFR1 expression. Moreover, chronic morphine infusion
increased TNFR1-specific expression in neuron in morphine-tolerant rat spinal cords, and this
effect was almost completely inhibited by resveratrol treatment prior to morphine challenge.
Conclusion: Resveratrol restores the antinociceptive effect of morphine by reversing morphine
infusion-induced spinal cord neuroinflammation and increase in TNFR1 expression. Theave no conflicts of interest relevant to this article.
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446 R.-Y. Tsai et al.reversal of the morphine-induced increase in TNFR1 expression by resveratrol is partially due
to reversal of the morphine infusion-induced increase in HDAC1 expression. Resveratrol pre-
treatment can be used as an adjuvant in clinical pain management for patients who need
long-term morphine treatment or with neuropathic pain.
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Morphine is a powerful analgesic for treating severe pain,
but its long-term administration induces tolerance, which
hampers its clinical use. Morphine tolerance is a complex
physiologic process,1 and various mechanisms have been
proposed, such as glutamatergic receptor activation2 and
neuroinflammation.3,4 The opioid-induced hyperalgesia
observed in tolerant rats5 is similar to the symptoms
observed in neuropathic pain patients, in whom opioids
provide only a limited analgesic effect. Recent studies have
suggested that expression of pain-associated genes in sen-
sory neurons and glial cells is involved in the generation and
maintenance of neuropathic pain6,7 and morphine toler-
ance.8 Epigenetic processes induce heritable changes in
gene expression and function and regulate the transcription
and expression of pro- or antinociceptive genes after
chronic morphine exposure.8,9 Epigenetic modifications in-
fluence the inflammatory process,10 and an inhibitor of
histone deacetylase (HDAC) decreases expression of cyto-
kines, especially tumor necrosis factor-alpha (TNF-a).11
However, the contribution of histone acetylation to the
development of morphine tolerance is not clear. Binding of
inflammatory cytokines to their receptors may modulate
epigenetic processing. In the central nervous system, TNF-
a, which is constitutively expressed in neurons and glial
cells and is released from these cells on stimulation,12 plays
a crucial role in the glialeneuron interaction that affects
both neuropathic pain13 and drug abuse.14 TNF inhibitors
are widely used for the treatment of inflammatory dis-
eases. Our recent studies showed that the binding of TNF-a
to TNF receptors (TNFRs) modulates TNF-a-mediated in-
flammatory signal transduction.2,15
Polyphenolic compounds are found in many plants, and
one of these compounds, resveratrol, has been shown to
have beneficial effects as a neuroprotective,16 anticancer,
and anti-inflammation agent.17 These results imply that
resveratrol may have an analgesic activity. Resveratrol has
been shown to inhibit nitric oxide generation and TNF-a
expression in diabetic rats and spinal nerve-ligated rats.16,18
In our previous study, resveratrol reversed the morphine
infusion-induced increase in expression of the proin-
flammatory cytokines TNF-a, interleukin (IL)-1b, and IL-6
and microglia activation.4 These results suggest that
resveratrol has the potential for relieving pain in patients
who develop morphine tolerance. The mechanism by which
acute resveratrol treatment inhibits neuroinflammation
after development of morphine tolerance remains unclear.
The present study is the first to examine this mechanism
using morphine-evoked neuroinflammation in morphine-
tolerant rats, and showed that long-term morphineinfusion resulted in increased expression of TNF-a and TNFR1
and that these effects were reversed by resveratrol, possibly
by reversing the morphine infusion-induced increase in
HDAC1 expression seen in the tolerant rat spinal cord.
Methods
Construction of the intrathecal catheters
Each intrathecal (i.t.) catheter was constructed by insert-
ing a 3.5-cm silastic tube (Dow Corning, Midland, MI, USA)
into an 8-cm polyethylene tube (0.008 inch inner diameter,
0.014 inch outer diameter; Spectranetics, Colorado Springs,
CO, USA) and sealing the joint with epoxy resin and silicon
rubber.
Animal preparation, i.t. drug delivery, and sample
collection
The use of rats in this study was reviewed and approved by
the National Defense Medical Center Animal Care and Use
Committee, Taipei, Taiwan. Male Wistar rats (350e400 g;
Biolasco Taiwan Co., Taipei, Taiwan) underwent a tail-flick
test (preinfusion test) and, on the following day, they were
anesthetized with phenobarbital (65 mg/kg, intraperito-
neally). Two i.t. catheters were implanted via the atlanto-
occipital membrane down to spinal cord segments L5eS3,
which control the tail flick reflex.19 Next, the rats were
returned to their home cages, with each rat being housed
individually and maintained on a 12-hour light/dark cycle
with food and water freely available. Rats with neurological
deficits were excluded.
To examine the effects of morphine tolerance on spinal
cord expression of HDAC1, TNF-a, and TNFR1 and TNFR2,
one of the catheters was connected to a miniosmotic pump
(Alzet, Cupertino, CA, USA), and either morphine (Sigma-
eAldrich, St. Louis, MO, USA; 15 mg/h) or saline was infused
for 120 hours at a rate of 1 mL/h. A tail-flick test was per-
formed prior to catheter insertion and after 24 hours, 48
hours, 72 hours, 96 hours, and 120 hours of infusion. Then
rats were sacrificed after 24 hours, 72 hours, and 120 hours
of morphine infusion by exsanguination under anesthesia
with isoflurane (Abbott Laboratories Ltd., Queenborough,
Kent, UK). The lumbar enlargement of the spinal cord was
removed to measure mRNA and protein expression, as
described in a later section.
To examine the effects of resveratrol on morphine
tolerance and protein expression, infusion was dis-
continued after 120 hours. After an interval of 3 hours, the
second catheter was used to inject rats i.t. with 5 mL of
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(DMSO)] or DMSO, then, after 30 minutes, with 15 mg of
morphine (5 mL in saline). The rats were then subjected to a
nociceptive tail-flick test every 30 minutes for the next 120
minutes. Later, the lumbar enlargement of the spinal cord
was removed for histochemical analysis and to measure
protein expression as described below. After each drug in-
jection, the catheter was flushed with 8 mL saline (dead
volume of the catheter). No abnormal motor function was
observed after injection of the test drugs.
Antinociceptive test
The tail-flick latency was measured using the hot water
immersion test (52  0.5C). The baseline latency was
approximately 2  0.25 seconds, and a 10-second cutoff
time was used. The tail-flick latency was used to measure
the antinociceptive effect of morphine as described previ-
ously.20,21 The rats were placed in plastic restrainers for
drug injection and antinociception assessment.
Spinal cord sample collection and membrane
fraction preparation
To collect samples of spinal cord, the rats were sacrificed by
exsanguination under isoflurane anesthesia. Laminectomy
was performed at the lower edge of the 12th thoracic
vertebra, and the lumbar enlargement of the spinal cord
immediately removed. Part of the sample was embedded in
optimal cutting temperature compound (Sakura Finetec
Inc., Torrance, CA, USA) for histochemistry, whereas the
dorsal region of the remainder was removed and was either
stored at 80C until used for Western blotting, cytokine
analysis, or real-time polymerase chain reaction (PCR) or
used immediately to prepare the membrane fraction using a
cytoplasmic, nuclear, and membrane compartment protein
extraction kit as recommended by the manufacturer (Bio-
chain Institute, Inc., Hayward, CA, USA). The membrane
fraction was checked for specificity by Western blotting, as
described in the next section, using mouse antibodies
against rat Naþ/Kþ ATPase, and then stored at 80C until
analysis for TNFR1 and TNFR2 expression.
Western blots
Whole homogenate
The supernatant prepared from a homogenate of the dorsal
portion of the lumbar spinal cord in the same way as for
measurement of TNF-a levels was used for Western blotting.
Samples containing 15 mg of proteinwere adjusted to a similar
volume in loading buffer [10% sodium dodecyl sulfate (SDS),
20% glycerin, 125mM Tris, 1mM EDTA, 0.002% bromphenol
blue, 10% b-mercaptoethanol] and denatured at 95C for 10
minutes. Then they were separated on a 10% SDS-
polyacrylamide gel electrophoresis gel and transferred to a
nitrocellulose membrane (Bio-Rad Laboratories Inc., Hercu-
les, CA, USA). The membrane was blocked for 1 hour at room
temperature in blocking buffer (5% nonfat milk in 50mM
TriseHCl, 154mM NaCl, and 0.05% Tween 20; pH 7.4) and
incubated overnight at 4C with polyclonal rabbit antirat
HDAC1 antibodies (Cell Signaling Technology Inc., Danvers,MA, USA; 1:2500 in blocking buffer), then for 1 hour at room
temperature with horseradish peroxidase-conjugated donkey
antirabbit immunoglobulin G antibodies (Chemicon, Teme-
cula, CA, USA; 1:5000 in blocking buffer). Bound secondary
antibodies were then detected using Chemiluminescenceplus
reagent (Perkin Elmer Life and Analytical Sciences, Waltham,
MA, USA) and a chemiluminescence imaging system (Syngene,
Cambridge, UK), and the optical density of each specific band
was measured using a computer-assisted imaging analysis
system (Gene Tools Match Software, Syngene, Cambridge,
UK). Finally, the blots were incubated at 56C for 18 minutes
in stripping buffer (0.0626 mol/L TriseHCl, pH 6.7, 2% SDS,
0.1 mol/L mercaptoethanol) and reprobed with a monoclonal
mouse antihistone H1 antibody (Abcam, Naka-Ku Nagoya,
Japan) as the loading control.
Membrane proteins
The membrane fraction was checked for specificity by
Western blotting as described above using a 1:2000 dilution
in blocking buffer of mouse antibodies against rat Naþ/Kþ
ATPase (Abcam, Naka-Ku Nagoya, Japan). Analysis of
membrane TNFR1 and TNFR2 protein levels was performed
by Western blotting as described above using polyclonal
rabbit antibodies against rat TNFR1 or TNFR2 (both from
Abcam, Cambridge Science Park, Cambridge, UK).
Measurement of TNF-a levels
The dorsal portion of the lumbar spinal cordwashomogenized
at 4C in RIPA lysis buffer (Upstate, USA, Inc., Charlottesville,
VA, USA); the homogenate was then centrifuged at 10,000g
for 30minutes at 4Cand the supernatant used for assays. The
protein concentration of samples was determined using the
bicinchoninic acid assay (Thermo Fisher Scientific Inc., Wal-
tham, MA, USA) with bovine serum albumin as the standard.
The TNF-a level in the supernatant was measured with a
simultaneous multiplexed format and a microbead and flow-
based protein detection system (Bio-Plex Suspension Array
System; Bio-Rad Laboratories Inc.) based on Luminex xMAP
technology. Each sample was adjusted to a protein concen-
tration of 1 mg/mL in the Bio-Plex kit lysis buffer, and the
lysate was incubated with antirat TNF-a antibody-coated
fluorescence-coded microbeads for 90 minutes at room
temperature; next, the beads were washed, incubated with
biotinylated second antibodies for 30 minutes at room tem-
perature, washed again, incubated with a streptavidin-
coupled phycoerythrin reporter system at room tempera-
ture for 10 minutes, washed, and finally analyzed by flow
cytometry. All spinal cord samples were assayed in triplicate,
and the TNF-a concentration was determined using a re-
combinant mouse TNF-a internal standard curve. The coef-
ficient of variation for controls ranged from 9% to 19% on the
exponential phase of the standard curve.
Immunocytochemistry and image analysis
The lumbar enlargement (L5eS3) of the spinal cord was
embedded in optimal cutting temperature compound
(Sakura Finetec Inc., USA), then frozen sections (5 mm)
were prepared and fixed by immersion in ice-cold acetone/
methanol (1:1) for 5 minutes. After a wash in ice-cold
Figure 1 Effect of morphine infusion on thermal hyper-
algesia. Time-course of changes in the tail-flick latency after
24 hours, 48 hours, 72 hours, 96 hours, or 120 hours of
continuous intrathecal infusion of saline (1 mL/h) or morphine
(15 mg/h; 1 mL/h). All data are expressed as the
mean  standard error of the mean (SEM) for five rats.
*p < 0.01, ***p < 0.0001 compared to the saline-infused group
(n Z 5 of each group). BL Z baseline; Mo Z morphine.
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incubation for 1 hour at room temperature in blocking
buffer (phosphate-buffered saline/10% normal goat serum/
0.1% Triton X-100), then were double-labeled by overnight
incubation at 4C with unlabeled polyclonal rabbit antirat
TNFR1 antibody and fluorescein isothiocyanate-labeled
mouse monoclonal antibody against rat CD11b/c (OX42;
microglial cell marker; Serotec, Oxford, UK), rat GFAP
(astrocyte marker; Molecular Probe, Eugene, OR, USA), or
NeuN (neuronal nuclei marker; Chemicon, USA), then for 1
hour at room temperature with rhodamine-labeled goat
antirabbit immunoglobulin G antibodies (Abcam) in block-
ing buffer. Images were then captured using an Olympus BX
50 fluorescence microscope (Olympus, Optical, Tokyo,
Japan) and a Delta Vision disconsolation microscopic sys-
tem operated by SPOT software (Diagnostic Instruments
Inc., Sterling Heights, MI, USA). Controls without primary
antibody were run to confirm the specificity of staining.
Quantitative real-time PCR
Total RNAwas extracted from thedorsal portion of the lumbar
spinal cord by homogenization of the sample at 4C in TRIzol
reagent (Invitrogen, Carlsbad, CA, USA). The first-strand
cDNA synthesis reaction was carried out using 1 mg of total
RNA, 50 ng of random hexamer primer, 0.5mM deoxynucleo-
tide mix, 10mM dithiothreitol, 1 RT buffer, and 200 U of
Superscript III reverse transcriptase (Invitrogen) in a total
volume of 20 mL, using conditions of 25C for 10minutes, 50C
for 50 minutes, and 85C for 5 minutes. Real-time PCR was
performed using an Applied Biosystems Prism 7500 Sequence
Detection systemwith FastStart Universal SYBR Green Master
mix (ROX; Roche Applied Science, Mannheim, Germany),
gene-specific primers, and diluted cDNA, using thermal cycle
conditions of 10 minutes at 95C, two-step PCR for 40 cycles
of 95C/15 seconds, and a final incubation at 60C for 1
minute. Fluorescence data were acquired during each
extension phase. After 40 cycles, a melting curve was
generated to verify primer specificities. All samples were
tested in triplicate. The amplification data were analyzed
using Applied Biosystems Prism Sequence Detection Software
version 1.1 (Roche Applied Science). To compare the relative
expression levels after different treatments, the expression
of the gene of interest was normalized to that of the GAPDH
control using the DDCT method recommended by the manu-
facturer. The primer sequences were TNF-a (NM_012675;
forward: 50-CACCGGCAAGGATTCCAA-30, reverse: 50-CACT-
CAGGCATCGACATTCG-30), HDAC1 (NM_001025409.1; for-
ward: 50-TGCTGGACTTACGAGACAGC-30, reverse: 50-GGAAGG
GCTGATGTGAAGC-30), TNFR1 (NM_013091.1; forward: 50-
AATGAGTGCACCCCTTGC-30, reverse: 50-CCTGGGGGTTT
GTGACATT-30), and TNFR2 (NM_130426.4; forward: 50-
GAGGCCCAAGGGTCTCAG-30, reverse: 50-GCTGCCATGGGAA-
GAATC-30).
Statistical analysis
All data are presented as the mean  standard error of the
mean. Statistical analysis was performed using SigmaStat 3.0
software (SYSTAT Software Inc., San Jose, CA, USA). Differ-
ences in tail-flick latency were analyzed using two-wayanalysis of variance (ANOVA; time and treatment), followed
by one-way ANOVA (at each time of the experiment) with a
post hoc StudenteNewmaneKeuls test. To compare immu-
noblotting results, the intensity of each test band was
expressed as the optical density relative to that of the
average optical density for the corresponding control band,
and the data were analyzed using one-way ANOVA, followed
by multiple comparisons with the StudenteNewmaneKeuls
post hoc test. A significant differencewas definedasp< 0.05.
Results
Effect of chronic morphine infusion on HDAC1
levels in spinal cord dorsal horn
As shown in Figure 1, i.t. infusion of saline for 120 hours did
not have any antinociceptive effect, as measured by the tail-
flick test (2.0 0.23 seconds). By contrast, in rats infused for
120 hours with morphine (15 mg/h), the maximum anti-
nociceptive effect was seen after 24 hours (9.12  0.18 s;
p < 0.0001), and tolerance was first seen at 48 hours
(5.73  0.34 s; p < 0.0001) and became maximal at 72e120
hours (2.82 0.51 seconds at 72 hours,pZ 0.0056; 2.36 0.3
seconds at 96 hours, pZ 0.0731; and 2.22  0.22 seconds at
120 hours, pZ 0.1078). As shown by immunoblotting of the
supernatants from spinal cord dorsal horn, tolerance was
associated with a significant time-dependent increase in
HDAC1 protein levels (Figures 2B and 2C; p Z 0.374,
p < 0.001, p < 0.001), but not mRNA levels (Figure 2A).
Effect of morphine infusion on TNF-a and TNFR
levels
As in our previous study,4 a significant increase in TNF-a
expression was seen in the dorsal spinal cord during
Figure 2 Time-course of changes in histone deacetylase 1
(HDAC1) levels in rat spinal cord dorsal horn during morphine
infusion. (A) HDAC1 mRNA and (B) protein levels were
measured in lumbar spinal cord dorsal horn lysate from rats
infused with saline (Con) or rats infused with morphine for 24
hours, 72 hours, and 120 hours. (C) Quantification of the data
from (B) for at least three rats (mean  standard error of the
mean). **p < 0.001 compared to the saline-infused control
group.
Resveratrol and morphine tolerance 449tolerance development in terms of both mRNA (Figure 3A;
p < 0.0001 at 24 hours, 72 hours, and 120 hours) and protein
(Figure 3B; p < 0.0001 at 24 hours, 72 hours, and 120
hours). As shown in Figures 4A and 4B, levels of TNFR1
mRNA (p Z 0.085 at 24 hours, p < 0.0001 at 72 hours and
120 hours) and TNFR2 mRNA (p Z 0.0038 at 24 hours,
p < 0.0001 at 72 hours, and pZ 0.0002 at 120 hours) in the
dorsal spinal cord also increased in a time-dependent
manner. By contrast, although TNFR1 protein levels in the
dorsal horn membrane fraction were increased at 24e120
hours (pZ 0.0001 at 24 hours, pZ 0.0002 at 72 hours, and
p Z 0.0004 at 120 hours), TNFR2 protein levels were not
(p Z 0.724 at 24 hours, p Z 0.711 at 72 hours, and
p Z 0.492 at 120 hours; Figures 4C and 4D). These results
suggest that TNF-a and TNFR1 play a critical role in themodulation of spinal synaptic transmission during both in-
duction and maintenance of morphine tolerance.
We then examined the effect of i.t. injection of
resveratrol 3 hours after the end of morphine infusion on
the antinociceptive effect of morphine and on HDAC1, TNF-
a, and TNFR1 expression.
Intrathecal resveratrol injection restores the
antihyperalgesia effect of morphine in morphine-
tolerant rats
As in our previous study,4 when the rats were infused for
120 hours with saline or morphine as described above, then
underwent challenge by i.t. injection of 15 mg of morphine
3.5 hours later, a significant antinociceptive effect (tail-
flick latency) was seen in saline-infused rats (9.5  0.35
seconds) but not in morphine-infused rats (2.0  0.15 sec-
onds; Figure 5). In addition, when the rats received an i.t
injection of 30 mg of resveratrol in DMSO 30 minutes prior to
morphine challenge, significant restoration of the anti-
nociceptive effect of morphine was seen in morphine-
tolerant rats, with a maximal effect at 60 minutes
(6.28  0.6 seconds, p < 0.001). This result showed that
resveratrol pretreatment could partially restore the anti-
nociceptive effect of morphine in morphine-tolerant rats.
Resveratrol reverses the increase in HDAC1
expression seen in the morphine-tolerant rat spinal
cord
As shown in Figure 6, 120 hours of morphine infusion
increased HDAC1 expression (2  0.15-fold; p < 0.005) in
the spinal cord lysate compared to rats infused with saline
for 120 hours, and this effect was almost completely
reversed by resveratrol treatment 3 hours after the end of
infusion (1.13  0.12-fold; p Z 0.33).
Resveratrol reverses the increase in
proinflammatory cytokine TNF-a levels seen in the
morphine-tolerant rat spinal cord dorsal horn
TNF-a levels in the rat spinal cord dorsal horn lysate were
measured using Bio-Plex cytokine assay kits. As shown in
Figure 7, TNF-a levels were significantly higher in
morphine-infused/DMSO-injected rats (57.66  2.74 pg/
mg; p < 0.0001) than in saline-infused/DMSO-injected rats
(5.0  0.68 pg/mg), and this effect was considerably
reversed by i.t. injection of resveratrol 3 hours after the
end of morphine infusion (20.83  3.09 pg/mg; p < 0.0001
compared to morphine-infused/DMSO-injected rats).
Resveratrol reverses the morphine-evoked
increase in TNFR1 expression in spinal cord dorsal
horn cell membranes and in activated glial cells
Figure 8 shows Western blots of TNFR1 levels in cell mem-
branes from the various groups, with the value for the
saline-infused/DMSO-injected group set as 1. TNFR1 levels
were significantly higher in morphine-infused/DMSO-
injected rats (2.73  0.74; p < 0.0001) than in saline-
Figure 3 Time-course of changes in tumor necrosis factor-alpha (TNF-a) levels in rat spinal cord dorsal horn after morphine
infusion. (A) TNF-amRNA and (B) protein levels were measured in lumbar spinal cord dorsal horn from rats infused with saline (Con)
or rats infused with morphine for 24 hours, 72 hours, and 120 hours. All data are expressed as the mean  standard error of the
mean for three rats. ***p < 0.0001 compared to the saline-infused group.
450 R.-Y. Tsai et al.infused/DMSO-injected rats, and this effect was completely
reversed by i.t. injection of resveratrol 3 hours after the
end of morphine infusion (0.72  0.03; p < 0.0001).
Figure 9 shows the results of a double-staining immu-
nohistochemical study, which demonstrate that, in the
spinal cord dorsal horn of morphine-tolerant rats
(Mo þ DMSO), the morphology of astrocytes (GFAP) and
microglia (OX42), but not neurons (NeuN), changed from a
ramified shape to an ameboid shape, showing the activation
of these cells in the morphine-tolerant rat spinal cor. In
addition, strong TNFR1 immunoreactivity was seen in neu-
rons (white arrows), but not in glial cells, in the same rats.
Again, both effects were reversed by resveratrol treatment
3 hours after the end of morphine infusion. These resultsFigure 4 Effects of morphine infusion on tumor necrosis factor r
dorsal horn and protein levels in membranes. Time-course of chang
horn and corresponding protein levels in (C and D) membranes from
24, 72, and 120 hours. All data are expressed as the mean  standa
compared to the saline-infused group.support the idea that activation of TNFR1 signaling in the
morphine-tolerant rat spinal cord might play an important
role in the development of the thermal hyperalgesia seen in
morphine-tolerant rats.Discussion
Resveratrol has been widely studied in the treatment of
inflammatory disorders.16,22 A pilot study showed that
intraperitoneal injection of resveratrol dramatically im-
proves the antinociceptive effect in carrageenan-evoked
hyperalgesia rats.23 Similarly, our study demonstrated
that i.t. injection of resveratrol restored theeceptor 1 (TNFR1) and 2 (TNFR2) mRNA levels in rat spinal cord
es in (A) TNFR1 and (B) TNFR2 mRNA levels in spinal cord dorsal
rats infused with saline (Con) or rats infused with morphine for
rd error of the mean for three rats. **p < 0.001, ***p < 0.0001
Figure 5 Resveratrol restores the antinociceptive effect of
morphine in morphine-tolerant rats. At 3 hours after the end of
120 hours of morphine or saline infusion, the rats were injected
with either dimethyl sulfoxide (DMSO; 5 mL) or resveratrol
(30 mg in 5 mL of DMSO), then, 30 minutes later, underwent
morphine challenge (15 mg in 5 mL of saline) and the tail-flick
latency was measured every 30 minutes for 120 minutes. All
data are expressed as the mean  standard error of the mean
for three rats. *p < 0.01, **p < 0.001 compared to the Sal/
DMSO group. ##p < 0.001; ###p < 0.0001 compared to the Mo/
DMSO group. Sal/DMSO Z saline infusion plus DMSO injection;
Sal/R Z saline infusion plus resveratrol injection; Mo/
DMSO Z morphine infusion plus DMSO injection; Mo/
R Z morphine infusion plus resveratrol injection.
Figure 6 Resveratrol reverses the increase in histone
deacetylase 1 (HDAC1) levels seen in the morphine-tolerant rat
spinal cord. The infusion/injection protocol described in the
legend to Figure 5 was used, then spinal cord dorsal horn were
collected 120 minutes after morphine challenge. (A) Western
blot analysis of HDAC1 levels in spinal cord dorsal horn from the
indicated groups. (B) Quantification of the data from (A)
expressed relative to the Sal þ DMSO groups using histone 1 as
the loading control. The data are the mean  standard error of
the mean for three rats per group. **p < 0.005 compared to the
Sal/DMSO group. ##p < 0.005 compared to the morphine-
tolerant group (Mo/DMSO). DMSO Z dimethyl sulfoxide.
Figure 7 Resveratrol reverses the morphine-evoked increase
in tumor necrosis factor-alpha (TNF-a) expression. The infu-
sion/injection protocol described in the legend to Figure 5 was
used, then spinal cord dorsal horn were collected 120 minutes
after morphine challenge and tested for TNF-a levels. The
results are expressed as the mean  standard error of the
mean, with three rats per group. ***p < 0.0001 compared to
the Sal/DMSO group. ###p < 0.0001 compared to the morphine-
tolerant group (Mo/DMSO). DMSO Z dimethyl sulfoxide.
Resveratrol and morphine tolerance 451antinociceptive effect of morphine in morphine-tolerant
rats and that this was associated with reversal of the
morphine-induced increase in HDAC1, TNF-a, and TNFR1
levels and with reversal of astrocyte and microglia activa-
tion in the morphine-tolerant rat spinal cord.
Spinal cord glia activation seems to be a common
mechanism of neuropathic pain and morphine tolerance.24
The importance of neuroimmune activation in the initia-
tion and facilitation of morphine tolerance has been
demonstrated.25 Long-term morphine administration leads
to activation of calcitonin gene-related peptide (CGRP)
receptors, which differentially control the synthesis and
release of TNF-a by astrocytes and microglia via the p38
and ERK signaling pathways, and blockade of CGRP signaling
in astrocytes and microglia has been shown to prevent TNF-
a release and subsequent development of tolerance.26
Previous studies have shown that chronic morphine treat-
ment induces glia activation and expression of the proin-
flammatory cytokines TNF-a, IL-1b, and IL-6 in the rat
spinal cord.27,28 The i.t. coadministration of morphine with
a glia metabolic inhibitor29 or a glial modulator24 signifi-
cantly attenuates morphine tolerance. Thus, limiting the
production of proinflammatory cytokines by activated
microglia and astrocytes should help reverse morphine
tolerance. In this study, chronic morphine infusion induced
significant increases in TNF-a mRNA and protein levels in
the dorsal horn of the rat spinal cord, and the increase in
TNF-a protein levels was almost completely reversed by
subsequent i.t. injection of resveratrol. This suggests thatresveratrol can regulate proinflammatory cytokine expres-
sion at both the transcriptional and translational levels by
interacting with transcriptional factors (such as NFkp65
protein) and related signaling pathways.
The excitatory amino acid glutamate plays an important
role in excitatory synaptic plasticity and morphine
Figure 8 Resveratrol reverses the morphine-induced in-
crease in TNFR1 expression. The infusion/injection protocol
described in the legend to Figure 5 was used. (A) Western blot
analysis of TNFR1 levels in the membrane fraction of the
different treatment groups; Naþ/Kþ ATPase was used as the
internal control. (B) Quantification of the data from (A)
expressed relative to the Sal/DMSO value. The data are the
mean  standard error of the mean for three rats per group.
**p < 0.001; ***p < 0.0001 compared to the Sal/DMSO group.
###p < 0.0001 compared to the morphine-tolerant group (M/
DMSO). DMSO Z dimethyl sulfoxide; TNFR1 Z tumor necrosis
factor receptor 1.
Figure 9 Resveratrol reverses morphine infusion-induced neuroi
legend to Figure 5 was used, then samples were collected 120 min
double-labeled for TNFR1 (red labeling) and NeuN (neurons, top ro
row) (green labeling); overlap of the two labels is seen as yellow
panels, morphine-tolerant group (Mo/DMSO); right panels, morph
representative of those for samples from three rats. Scale bar Z
factor receptor 1.
452 R.-Y. Tsai et al.tolerance.30 Synaptic glutamate levels are tightly
controlled by transporters on neurons and astrocytes,31 and
the glutamate transporter GLT-1 is especially important in
the rapid clearance of most synaptic glutamate in the
central nervous system.20 Enhanced nuclear factor kappa B
(NF-kB) activity increases TNF-a expression, which, in turn,
inhibits GLT-1 expression, leading to an increase in the
synaptic glutamate concentration, resulting in cell toxicity
and cell death in neuroinflammatory diseases.32 Moreover,
TNF-a can block glutamate reuptake via activated TNFR1,
and this interaction between TNF-a and glutamate helps
maintain glia/neuronal activation and further amplifies
nociceptive signaling.33 After nerve lesion, TNF-a levels are
significantly increased in dorsal root ganglia neurons, and
this is associated with thermal hyperalgesia and TNFR1
upregulation.34,35 These results indicate that modulation of
TNF-a and TNFR1 expression could be a biological target for
the treatment of morphine tolerance. Our study supports
the idea that reversal of morphine infusion-induced spinal
neuroinflammation, and TNF-a and TNFR1 expression can
help restore the antinociceptive effect of morphine after
long-term morphine exposure. As per our recent studies
and the present study, we found that morphine infusion
induces glia cells to release TNF-a, but the TNFR1 was
specifically expressed on neuron plasma membrane. These
results suggest that TNF-a activates cytokine-mediated
neuroinflammation in spinal glia cells and subsequently,
via a paracrine way, induced TNFR1 expression in neurons.
Although the role of TNF-a in morphine tolerance has been
intensively studied, the temporal profile of TNF-a and TNFRnflammation. The infusion/injection protocol described in the
utes after morphine challenge and sections of the dorsal horn
w), GFAP (astrocytes, middle row), or OX42 (microglia, bottom
(white arrows). Left panels, control group (Sal/DMSO); central
ine infusion plus resveratrol injection (Mo/R). The results are
50 mm. DMSO Z dimethyl sulfoxide; TNFR1 Z tumor necrosis
Resveratrol and morphine tolerance 453expression following the development of morphine toler-
ance has not. In the present study, we demonstrated that
an increase in mRNA and protein levels of TNF-a and TNFR1,
but not TNFR2, was seen in the spinal cord after 24 hours of
morphine infusion and persisted throughout the 5 days of
infusion. This suggests that TNFR1, but not TNFR2, is
involved in TNF-a-mediated signaling transduction in
morphine tolerance induction and maintenance. Silva
et al36 found that resveratrol acts as a natural anti-TNF-a
molecule and inhibits proinflammatory cytokine expression
in TNF-a-treated dendritic cells by inhibiting NF-kB trans-
location to the nucleus. Our results also showed that
resveratrol treatment of morphine-tolerant rats converted
activated spinal glia to an inactive ramified state. More-
over, resveratrol reversed the morphine-induced increase
in TNFR1 expression seen in neurons, but not in glia cells
(both astrocytes and microglia). These results suggest that
resveratrol can modify neuroneglia communication in
morphine-induced neuroinflammation.
Histone deacetylation by HDACs, a common epigenetic
modification of chromatin, is associated with expression of
genes coding for cytokines.37 The mammalian genome
contains at least 18 HDAC genes, and the encoded proteins
are differentially distributed in the nervous system.38 HDAC
inhibitors, which prevent the removal of acetyl groups from
histones, result in amelioration of symptoms in many in-
flammatory diseases in animals.39,40 These results suggest
that regulation of histone acetylation might be useful in the
management of clinical hyperalgesia. The results of our
recent study41 also support the idea that i.t. injection of
baicalin, another Chinese herb with similar anti-
inflammatory activity to resveratrol, results in significant
reversal of the spinal nerve ligation-induced increase in
HDAC1 expression, which is associated with restoration of
the antinociceptive effect of morphine. Resveratrol has
been reported to act as an HDAC1 inhibitor and to inhibit
the inflammatory cascade and the expression of NF-kB,
survivin, and sirtuin 1.42e44 Similarly, our present study also
showed that resveratrol reversed the morphine infusion-
induced increases in HDAC1, TNF-a, and TNFR1 expression
and glial cell activation, thus restoring the antinociceptive
effect of morphine. Our results therefore suggest that
resveratrol may regulate epigenetic processing, an effect
that might be useful in clinical pain management.
This study is an integral first step in assessing the use-
fulness of resveratrol in morphine-evoked hyperalgesia and
the association between TNF-a-related signaling and HDAC1
expression in morphine tolerance. It provides new evidence
that resveratrol may have potential as an analgesic adju-
vant in clinical pain management, particularly in patients
who need long-term morphine treatment and in morphine-
tolerant patients who require better pain relief.Acknowledgments
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